Vivodyne is thrilled to announce the successful raising of $40 million in new funding, marking a pivotal moment in our journey to transform drug discovery and accelerate advancements in human health. Our innovative company, where cutting-edge biotechnology meets artificial intelligence and advanced computing, is dedicated to revolutionizing the way therapies are developed by harnessing the power of lab-grown 3D human tissues. These human tissue models allow for highly scalable and dynamic drug testing, enabling researchers to simulate complex biological processes with unprecedented accuracy. With this fresh capital infusion, we are poised to expand our research capabilities, scale up our testing platforms, and drive forward our mission to discover breakthrough cures for a range of human diseases. The investment will not only further our development of state-of-the-art platforms but also strengthen collaborations with academic and industry partners, ensuring that our innovative technologies continue to evolve and make a real impact on patient outcomes. As we invest in new technologies and expand our research teams, we remain committed to maintaining the highest standards of scientific rigor and innovation. We acknowledge that this milestone is the result of dedicated partnerships, groundbreaking research, and an unwavering commitment to transforming the landscape of drug discovery. With renewed momentum and strategic resources, Vivodyne is ready to set new benchmarks in precision medicine and usher in a new era where rapid, reliable, and scalable drug testing can lead to life-changing treatments. This funding round is an exciting leap forward in our ongoing mission to reimagine how medical breakthroughs are achieved and to ultimately improve lives across the globe.
Vivodyne Secures $40M Series A to Revolutionize Drug Discovery with 3D Human Tissue Innovations
Recently funded · $40.0M Series aPharmaceuticals
Get the full Vivodyne company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
